AQR Capital Management
CSTL icon

AQR Capital Management’s Castle Biosciences CSTL Stock Holding History

AQR Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59M Buy
64,880
+999
+2% +$32.7K ﹤0.01% 2500
2025
Q4 		$2.48M Buy
63,881
+13,039
+26% +$420K ﹤0.01% 2003
2025
Q3 		$1.16M Buy
50,842
+1,612
+3% +$32.7K ﹤0.01% 2342
2025
Q2 		$1.01M Sell
49,230
-87,792
-64% -$1.63M ﹤0.01% 2204
2025
Q1 		$2.74M Buy
137,022
+115,907
+549% +$2.87M ﹤0.01% 1438
2024
Q4 		$563K Buy
+21,115
New +$643K ﹤0.01% 2187
2024
Q2 		– Sell
-22,795
Closed -$505K – 2615
2024
Q1 		$505K Buy
22,795
+8,592
+60% +$187K ﹤0.01% 1954
2023
Q4 		$307K Sell
14,203
-240
-2% -$4.22K ﹤0.01% 2057
2023
Q3 		$244K Buy
+14,443
New +$253K ﹤0.01% 2080
2021
Q2 		– Sell
-6,381
Closed -$437K – 2239
2021
Q1 		$437K Sell
6,381
-4,446
-41% -$334K ﹤0.01% 1886
2020
Q4 		$727K Buy
+10,827
New +$587K ﹤0.01% 1644

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's CSTL Position: Q1 2026 in Review

AQR Capital Management increased its Castle Biosciences (CSTL) stake by 1.6% in Q1 2026, buying an estimated $32.7K and bringing the position to 64,880 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2500.

AQR Capital Management first reported a position in CSTL in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.74M in Q1 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • AQR Capital Management held 64,880 shares of Castle Biosciences worth $1.59M as of Q1 2026.
  • AQR Capital Management bought 999 Castle Biosciences shares in Q1 2026, an estimated $32.7K.
  • Castle Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2500 holding.
  • AQR Capital Management first reported a position in Castle Biosciences in Q4 2020 and has held it in 11 quarters since.
  • AQR Capital Management's Castle Biosciences position peaked at $2.74M in Q1 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.